FDA Looks To Outcomes Research In Move To Quantify Risk/Benefit Decisions
Executive Summary
Outcomes trials appear to hold a strong position in the future of new drug development. But outcomes data is not the only factor FDA will consider as it moves toward setting new standards for quantification of risk and benefit, the agency said at a recent drug safety conference